Alexander V. Maltsev

Papers

• Maltsev A.V., Funikov S., Rezvykh A., Teterina E., Nebogatikov V., Burov A., Bal N.V., Ustyugov A., Karpov V., Morozov A. Chronic Administration of Non-Constitutive Proteasome Inhibitor Modulates. International Journal Of Molecular Sciences. 2023. V. 24. N. 9. P. 8172. DOI: 10.3390/ijms24098172
• Maltsev A.V., Nikiforova A.B., Bal N.V., Balaban P.M. Amyloid Aβ(25-35) Aggregates Say 'NO' to Long-Term Potentiation in the Hippocampus through Activation of Stress-Induced Phosphatase 1 and Mitochondrial Na(+)/Ca(2+) Exchanger. International Journal Of Molecular Sciences. 2022. V. 23. N. 19. P. 11848. DOI: 10.3390/ijms231911848
• Maltsev A.V., Roshchin M.V., Bezprozvanny I., Smirnov I.V., Vlasova O., Balaban P.M., Borodinova A.A. Bidirectional regulation by "star forces": Ionotropic astrocyte's optical stimulation suppresses synaptic plasticity, metabotropic one strikes back. Hippocampus. 2022. V. 33. N. 1. P. 18-36. DOI: 10.1002/hipo.23486
• Fonar G., Polis B., Sams D.S., Levi A., Malka A., Bal N.V., Maltsev A.V., Elliott E., Samson A.O. Modified Snake α-Neurotoxin Averts β-Amyloid Binding to α7 Nicotinic Acetylcholine Receptor and Reverses Cognitive Deficits in Alzheimer's Disease Mice. Molecular Neurobiology. 2021. V. 58. N. 5. P. 2322-2341. DOI: 10.1007/s12035-020-02270-0
• Maltsev A.V., Bal N.V., Balaban P.M. Serine/Threonine Phosphatases in LTP: Two B or Not to Be the Protein Synthesis Blocker-Induced Impairment of Early Phase. International Journal Of Molecular Sciences. 2021. V. 22. N. 9. P. 4857. DOI: 10.3390/ijms22094857
• Maltsev A.V., Funikov S., Burov A., Spasskaya D., Ignatyuk V., Astakhova O.G., Lyupina Y., Deikin A., Tutyaeva V., Bal N.V., Karpov V., Morozov A. Immunoproteasome Inhibitor ONX-0914 Affects Long-Term Potentiation in Murine Hippocampus. Journal Of Neuroimmune Pharmacology. 2021. V. 16. N. 1. P. 7-11. DOI: 10.1007/s11481-020-09973-0
• Maltsev A.V., Bal N.V., Balaban P.M. LTP suppression by protein synthesis inhibitors is NO-dependent. Neuropharmacology. 2019. V. 146. P. 276-288. DOI: 10.1016/j.neuropharm.2018.12.009